Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Thiazolidinediones (TZDs) exhibit limited efficacy as monotherapy in cancer treatment.
• Pre-clinical data on TZDs' anti-cancer activity are conflicting, showing both tumor promotion and inhibition.
• Clinical inefficacy of TZDs contrasts with their potential when combined with other agents.

Purpose of the Study:

• To investigate the therapeutic potential of combining thiazolidinediones with 'master modulators' of tumors.
• To explore the concept of anakoinosis (tumor cell communication reprogramming) as a novel cancer therapy.
• To overcome limitations of traditional targeted therapies, such as resistance and tumor heterogeneity.

Main Methods:

• Combination therapy involving thiazolidinediones and various master modulators (transcriptional modulators, low-dose chemotherapy, epigenetic agents, COX-2 inhibitors, IMiDs).
• Focus on inducing anakoinosis through modulated gene expression, including up-regulation of tumor suppressor genes.
• Evaluating the impact on tumor tissue, host organ, and organismal communication.

Main Results:

• Combination therapy with TZDs and master modulators induces clinically relevant reprogramming of tumor tissues (anakoinosis).
• This approach can diversify palliative care and potentially lead to complete remission in refractory metastatic diseases and hematologic neoplasias.
• Re-modulation of gene expression, such as up-regulating tumor suppressor genes, aids cancer control.

Conclusions:

• Anakoinosis, induced by specific combinations of master modulators with Peroxisome proliferator-activated receptor γ (PPARγ) agonists, represents a novel therapeutic pillar.
• This strategy effectively overcomes common obstacles associated with targeted therapies, including resistance and molecular heterogeneity.
• Re-establishing normal cellular communication and function within tumor tissues offers a promising alternative to conventional cytotoxic approaches.